Navigation Links
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Date:10/20/2009

NANJING, China, Oct. 20 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

Headquartered in Long Island, OSI is a NASDAQ listed pharmaceutical company specialized in discovery and development of innovative molecular targeted therapies. OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers. The company completed a phase I dose escalation study of OSI-930 in healthy volunteers. A phase I single agent dose escalation study in cancer patients has identified a recommended phase II dose and a phase Ib dose escalation study with erlotinib has also identified a recommended dose for the combination. Both phase I studies in cancer patients have been reported at recent ASCO meetings.

"OSI-930 has potential to help cancer patients, and we are delighted to cooperate with OSI Pharmaceuticals to promote this treatment in China," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "We believe that this is a groundbreaking agreement which will become a model for future R&D cooperation between Chinese and foreign pharmaceutical companies."

'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  Research and Benchmarking ... sixth Medical Affairs Roundtable on Thursday, ... a virtual roundtable to discuss "Medical Affairs, Role ... Best Practices, Medical Affairs Consortium provides Medical Affairs ... the key challenges they face. The consortium has ...
(Date:5/22/2015)... 2015 /CNW/ - The Taskforce representing Canada,s ... the hard work that the Minister and Health Canada have ... program recognizes the needs of the thalidomide survivors, and more ... year, tax free, with annual adjustments for inflation. ... payments of $100,000 based on the severity of their disability, ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:5/22/2015)... “It’s like learning an new language,” ... President of Clinical Operations/Education and Training at Harmony ... how care is coded and reimbursed.” , Harmony ... reimbursement, operations and compliance consulting, as well as ... a new series of day-long seminars on the ...
(Date:5/22/2015)... 2015 Coordinating care for people ... Historically providers have not been reimbursed or rewarded ... 2015, Medicare has paved the way by offering ... the launch of Oculus Health , an ... using the platform will now be able to ...
(Date:5/22/2015)... Power Systems is proud to announce the sponsorship ... Drobeck is in his second year of racing in the ... Missoula Fire Department in Missoula, MT. He entered the triathlon ... his career, he has had 15 1st Place finishes. In ... finishes in all seven of his 2014 races, including two ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 According to ... hub for drug related death, totaling almost 2,500 confirmed drug ... reported by state officials, totals 2,489 deaths stemming from legal ... out, Pennsylvania loses seven people every day to fatal overdoses ... been singled out as one of the most rife with ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
... percent; real number may be as low as 4 percent, ... new, closer look at data on Caesarean section births in ... surgical deliveries is far lower than previously thought. , When ... C-sections being performed in the United States on women who ...
... conducted by University of Denver (DU) Associate Professor Rene ... undergraduate students to wash their hands more frequently after ... researchers posted messages in the bathrooms of two DU ... on you, wash your hands" or "You just peed, ...
... , ... Phoenix, AZ (Vocus) December 23, 2008 -- Adding to a ... results released in the December 23rd issue of Circulation further emphasized the ... sedentary job structures most Americans fall far short of the minimum recommended ...
... and Translational Science (CCTS) has awarded 18 grants ... grant program. The grants, which range from $2,000 ... translational science that, if successful, might lead to ... funds from a 2006 Clinical and Translational Science ...
... Mixing prescription, nonprescription meds poses dangers, researchers say , , ... 4 percent of older adults in the United States ... put them at risk for potentially dangerous interactions, a ... adults over 65 account for more than 175,000 emergency ...
... Women who did weight-bearing sports such as swimming had greater ... News) -- Doing weight-bearing exercise during adolescence may help women ... says. , Published online Dec. 22 in the British ... conclusions by looking at the teenage exercise habits of 46 ...
Cached Medicine News:Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 2Health News:Rate of Unnecessary C-Sections Far Lower Than Thought 3Health News:University of Denver uses 'gross' messaging to increases handwashing, fight Norovirus 2Health News:Treadmill Desks to the Rescue: Weight Control and Activity Critical in Preventing Heart Failure 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 2Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 3Health News:Rockefeller University's Center for Clinical and Translational Science funds 18 new pilot studies 4Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Standard/Conventional Blade. Stainless steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: